Should I Buy ENGN? ENGN 2026 Analysis

Should You Buy enGene Holdings Inc (ENGN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

9.550

1 Day change

7.79%

52 Week Range

12.250

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient trader: near-term catalysts are limited and the short-term technical picture is weakening.
Price (pre-market ~9.41) is below the pivot (10.533), implying overhead resistance and a tougher path to immediate upside.
Despite bullish longer-term moving averages, MACD is negative and deteriorating and RSI is subdued, which often precedes more chop/downside.
Wall Street is broadly constructive on the multi-year thesis (high price targets), but that’s more relevant for longer holding periods than immediate entry.

Technical Analysis

Trend/Momentum: Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), suggesting the broader structure isn’t broken, but momentum is currently soft.
MACD: Histogram -0.0943 and negatively expanding = bearish momentum strengthening in the near term.
RSI (6): 41.3 = weak/neutral; not oversold enough to signal a high-conviction bounce.
Key levels:
- Support: S1 9.238 (current price is only slightly above), then S2 8.438.
- Resistance: Pivot 10.533, then R1 11.828.
Pattern-based forward bias (provided): +0.28% next day, +2.61% next week, but -1.97% next month → favors short-term bounce potential but weak intermediate follow-through.

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Positive Catalysts

- Analyst community has turned more optimistic following updated LEGEND Phase 2 data; multiple firms carry Outperform/Overweight-type views.
- Differentiation narrative: practice-friendly profile for detalimogene and competitive 6-month complete response metrics versus peers (per bullish analysts).
- Longer-dated potential catalyst: pivotal/high-risk NMIBC study update referenced for 2H 2026 (not near-term, but meaningful to the thesis).

Neutral/Negative Catalysts

- No news in the recent week and limited near-term catalysts (also highlighted by UBS) reduces the probability of an immediate upside re-rate.
- Mixed competitive read-through: UBS notes results improved but still viewed as below some competitors (e.g., CG Oncology / J&J programs), pressuring near-term sentiment.
- Current technical momentum is weakening (negative MACD expansion) and price is below the pivot, increasing odds of a retest of support (~9.24 / 8.44).
- Trading trends: hedge funds and insiders are neutral with no notable recent accumulation signals.

Financial Performance

Latest reported quarter: 2025/Q4.
Revenue: 0 (no commercial revenue; unchanged YoY).
Net income: -$37.88M (improved vs prior year; loss narrowed materially per YoY change).
EPS: -0.74 (improved YoY).
Takeaway: improving loss profile, but still a pre-revenue biotech setup—price action will be more catalyst/sentiment-driven than fundamental revenue growth right now.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: clear positive skew in ratings/targets after trial updates.
Jefferies (2026-01-30): Initiated Buy, PT $28.
UBS (2025-11-12): Neutral, PT raised to $10 (cites limited near-term catalysts and later entry).
Oppenheimer (2025-11-12): Outperform, PT $33.
Morgan Stanley (2025-11-12): Overweight, PT $19.
Citizens JMP (2025-11-12): Outperform, PT $21.
Raymond James (2025-11-11): Upgraded to Strong Buy, PT $27.
Wall Street pros vs cons:
- Pros: competitive updated efficacy signal, improved study design alignment, sizable NMIBC opportunity, favorable “practice-friendly” positioning.
- Cons: timing (later market entry), fewer near-term catalysts, competitive landscape may cap near-term multiple expansion.
Influential/politician trading: No recent congress trading data available.

8 Analyst Rating

Wall Street analysts forecast ENGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ENGN is 23.75 USD with a low forecast of 10 USD and a high forecast of 33 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

1 Hold

0 Sell

Strong Buy

Current: 8.860

Low

Averages

23.75

High

Current: 8.860

Low

Averages

23.75

High

Jefferies

initiated

$28

AI Analysis

2026-01-30

Reason

Jefferies

Price Target

$28

AI Analysis

2026-01-30

initiated

Reason

Jefferies initiated coverage of enGene with a Buy rating and $28 price target. The company is running a pivotal high-risk non-muscle invasive bladder cancer study with a key update in the second half of 2026, the analyst tells investors in a research note. The firm says enGene's interim data are competitive versus cretostimogene with a "clear differentiator" being the company's practice-friendly profile. enGene's detalimogene is "positioned to stand out," contends Jefferies.

UBS

Neutral

maintain

$4 -> $10

2025-11-12

Reason

UBS

Price Target

$4 -> $10

2025-11-12

maintain

Neutral

Reason

UBS raised the firm's price target on enGene (ENGN) to $10 from $4 and keeps a Neutral rating on the shares. EnGene reported updated Phase 2 LEGEND trial data for detalimogene in high-risk BCG-unresponsive non-muscle invasive bladder cancer, showing a 63% anytime complete response rate and 62% six-month CR under the amended protocol, an improvement from prior results but below competitors CG Oncology (CGON) and Johnson & Johnson (JNJ), the analyst tells investors in a research note. While the results confirm deta's activity, limited near-term catalysts and a later market entry contribute to a Neutral outlook.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ENGN

Unlock Now

ENGN Should I Buy

ENGN Should I Buy

Should You Buy enGene Holdings Inc (ENGN) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch